Cargando…

SGLT2 Inhibitors in Management of Severe Hypomagnesemia in Patients Without Diabetes: A Report of 4 Cases

Sodium/glucose cotransporter 2 (SGLT2) inhibitors have demonstrated a class effect in improving serum magnesium levels in patients with diabetes. Additionally, recent reports have shown their promising beneficial effects in the treatment of refractory hypomagnesemia in patients with diabetes. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Chintan V., Hammad, Nour, Bhasin-Chhabra, Bhavna, Rashidi, Arash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432792/ https://www.ncbi.nlm.nih.gov/pubmed/37602145 http://dx.doi.org/10.1016/j.xkme.2023.100697

Ejemplares similares

Sodium-Glucose Cotransporter 2 Inhibitors and Management of Refractory Hypomagnesemia Without Overt Urinary Magnesium Wasting: A Report of 2 Cases
por: Shah, Chintan V., et al.
Publicado: (2022)

SGLT2 Inhibitors for Treatment of Refractory Hypomagnesemia: A Case Report of 3 Patients
por: Ray, Evan C., et al.
Publicado: (2020)

Hypomagnesemia-Induced Hypocalcemia Successfully Treated With Sodium-Glucose Cotransport Inhibitor (SGLT-2i), a Case Report
por: Gandhi, Anand, et al.
Publicado: (2021)

Proton-pump inhibitor use amongst patients with severe hypomagnesemia
por: Seah, Sherry, et al.
Publicado: (2023)

Prevention of Hypomagnesemia in Diabetes Patients
por: Madihi, Yahya, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Sodium Glucose Co-Transporter2 (SGLT2) Inhibition for Refractory Hypomagnesemia in Monogenic Diabetes Type 5 (MODY 5)
por: Paul, Anju A, et al.
Publicado: (2021)

Familial Hypomagnesemia With Secondary Hypocalcemia: A Case Report
por: Gazzaz, Nour, et al.
Publicado: (2021)

Hypomagnesemia in type 2 diabetes mellitus
por: Dasgupta, Arundhati, et al.
Publicado: (2012)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Mechanisms of proton pump inhibitor‐induced hypomagnesemia
por: Gommers, Lisanne M. M., et al.
Publicado: (2022)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

Persistent severe hypomagnesemia caused by proton pump inhibitor resolved after laparoscopic fundoplication
por: Semb, Synne, et al.
Publicado: (2017)

Proton-pump Inhibitor-induced Severe Hypomagnesemia and Hypocalcemia are Clinically Masked by Thiazide Diuretic
por: Uehara, Atsuko, et al.
Publicado: (2019)

Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor
por: Monnerat, Sophie, et al.
Publicado: (2023)

Hypomagnesemia and Cardiovascular Risk in Type 2 Diabetes
por: Oost, Lynette J, et al.
Publicado: (2022)

An overview of diagnosis and management of drug‐induced hypomagnesemia
por: Liamis, George, et al.
Publicado: (2021)

Hypomagnesemia in Brachycephalic Dogs
por: Mellema, M.S., et al.
Publicado: (2014)

Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
por: Janett, Simone, et al.
Publicado: (2015)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
por: Nauck, Michael A
Publicado: (2014)

Diabetes Is the Main Factor Accounting for Hypomagnesemia in Obese Subjects
por: Lecube, Albert, et al.
Publicado: (2012)

Consequences of hypomagnesemia in type 2 diabetes mellitus patients
por: Nasri, Hamid
Publicado: (2014)

Diabetes-induced hypomagnesemia is not modulated by metformin treatment in mice
por: Kurstjens, Steef, et al.
Publicado: (2019)

Hypomagnesemia-Induced Seizures Post Severe Acute Kidney Injury
por: AL-Omairi, Anwar, et al.
Publicado: (2022)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Incidence of hypomagnesemia in the emergency room
por: Oliveira-Neto, PR, et al.
Publicado: (2003)

Hypomagnesemia: a clinical perspective
por: Pham, Phuong-Chi T, et al.
Publicado: (2014)

Hypomagnesemia in critically ill patients
por: Hansen, Bent-Are, et al.
Publicado: (2018)

Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies
por: Srinutta, Thawin, et al.
Publicado: (2019)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

Association between hypomagnesemia and severity of primary hyperparathyroidism: a retrospective study
por: Na, Ding, et al.
Publicado: (2021)

SAT229 Symptomatic Hypocalcemia In The Setting Of Crohn’s Disease With Severe Hypomagnesemia
por: Cuan, Katherine, et al.
Publicado: (2023)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
por: Kuriyama, Satoru, et al.
Publicado: (2023)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu, Shuangbo, et al.
Publicado: (2019)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
por: Sha, Wenjun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f743e23omrj5e8g0f8tehus3lt